{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:15Z","timestamp":1786987815977,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ebiom.2022.104092","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T05:57:04Z","timestamp":1654149424000},"page":"104092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Seung-Woo","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yeon","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Hwan","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Eun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-So","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Kil","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Sun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Hee","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104092_bib0001","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2022.104092_bib0002","first-page":"244","article-title":"Bladder cancer in 2010: how far have we come?","volume":"60","author":"Jacobs","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2022.104092_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/168682","article-title":"Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis","volume":"2015","author":"Redondo-Gonzalez","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ebiom.2022.104092_bib0004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ebiom.2022.104092_bib0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ebiom.2022.104092_bib0006","article-title":"Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions","author":"Pfail","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.ebiom.2022.104092_bib0007","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2022.104092_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive Transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ebiom.2022.104092_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","article-title":"Identification of an immunotherapy-responsive molecular subtype of bladder cancer","volume":"50","author":"Song","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104092_bib0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104092_bib0011","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-13-2761","article-title":"Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2022.104092_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176271","article-title":"Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going?","volume":"21","author":"Pardo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2022.104092_bib0013","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2022.104092_bib0014","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ebiom.2022.104092_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/0008-5472.CAN-17-0836","article-title":"YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells","volume":"78","author":"Ooki","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2022.104092_bib0016","doi-asserted-by":"crossref","first-page":"12205","DOI":"10.2147\/CMAR.S273442","article-title":"YAP triggers blader cancer proliferation by affecting the MAPK pathway","volume":"12","author":"Qiu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ebiom.2022.104092_bib0017","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","article-title":"Alternative Wnt signaling activates YAP\/TAZ","volume":"162","author":"Park","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104092_bib0018","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","article-title":"Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2022.104092_bib0019","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104092_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2022.104092_bib0021","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2022.104092_bib0022","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2022.104092_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ebiom.2022.104092_bib0024","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1158\/1078-0432.CCR-14-2680","article-title":"Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2022.104092_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051850","article-title":"Transcriptional profiling of advanced urothelial cancer predicts prognosis and response to immunotherapy","volume":"21","author":"Baek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2022.104092_bib0026","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA Damage and Repair Biomarkers of Immunotherapy Response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ebiom.2022.104092_bib0027","doi-asserted-by":"crossref","first-page":"45523","DOI":"10.1038\/srep45523","article-title":"YAP modulates TGF-beta1-induced simultaneous apoptosis and EMT through upregulation of the EGF receptor","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.104092_bib0028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41419-018-0515-z","article-title":"YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD","volume":"9","author":"Yu","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ebiom.2022.104092_bib0029","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ebiom.2022.104092_bib0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/08977194.2016.1180293","article-title":"The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer","volume":"34","author":"Wang","year":"2016","journal-title":"Growth Factors"},{"key":"10.1016\/j.ebiom.2022.104092_bib0031","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.ebiom.2022.104092_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2014.11.001","article-title":"Targeting the TGFbeta pathway for cancer therapy","volume":"147","author":"Neuzillet","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2022.104092_bib0033","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3892\/ol.2017.6621","article-title":"Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status","volume":"14","author":"Kang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ebiom.2022.104092_bib0034","first-page":"138","article-title":"Bladder cancer: improving NMIBC risk stratification","volume":"15","author":"Thoma","year":"2018","journal-title":"Nat Rev Urol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:15:45Z","timestamp":1762456545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422002730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":34,"alternative-id":["S2352396422002730"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104092","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104092"}}